Safety Data from a First-in-Human Phase 1 Trial of NKG2D Chimeric Antigen Receptor-T Cells in AML/MDS and Multiple Myeloma

被引：25

作者：

Nikiforow, Sarah ^{[1
,2
]}

Werner, Lillian ^{[3
]}

Murad, Joana ^{[4
]}

Jacobs, Matthew ^{[5
]}

Johnston, Lauren ^{[5
]}

Patches, Sarah ^{[5
]}

White, Randie ^{[5
]}

Daley, Heather ^{[5
]}

Negre, Helene ^{[5
]}

Reder, Jake ^{[4
]}

Sentman, Charles ^{[6
]}

Wade, Terri ^{[4
]}

Schmucker, Adam ^{[4
]}

Lehmann, Frederic Francois ^{[7
]}

Snykers, Sarah ^{[7
]}

Allen, Rachel ^{[7
]}

Dipietro, Heidi ^{[1
]}

Cummings, Kristen ^{[1
]}

Galinsky, Ilene ^{[1
]}

Munshi, Nikhil C. ^{[1
,2
]}

Schlossman, Robert L. ^{[2
]}

Stone, Richard M. ^{[1
,2
]}

Neuberg, Donna S. ^{[3
]}

Soiffer, Robert J. ^{[1
,2
]}

Dranoff, Glenn ^{[1
,2
]}

Ritz, Jerome ^{[1
,2
]}

Baumeister, Susanne H. C. ^{[8
]}

机构：

[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA

[2] Harvard Med Sch, Boston, MA USA

[3] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA USA

[4] Celdara Med LLC, Lebanon, NH USA

[5] Dana Farber Canc Inst, Boston, MA USA

[6] Geisel Sch Med, Dartmouth, NS, Canada

[7] Celyad, Celyad, SA, Australia

[8] Boston Childrens Hosp, Boston, MA USA

来源：

BLOOD | 2016年 / 128卷 / 22期

关键词：

D O I：

10.1182/blood.V128.22.4052.4052

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4052

引用

页数：5

共 50 条

[21] Expression of a TIM8 Peptide Reduces Alloreactivity of T Cells Facilitating an Allogeneic NKG2D Chimeric Antigen Receptor T Cell Therapy Approach
Michaux, Alexandre
Breman, Eytan
Mauen, Sebastien
Bolsee, Jennifer
Huberty, Fanny
Marijsse, Jerome
Violle, Benjamin
Jacques-Hespel, Celine
Marchand, Celine
Ramelot, Nancy
Houssa, Julien
Thuy Nguyen
Gilham, David
Agaugue, Sophie
MOLECULAR THERAPY, 2018, 26 (05) : 214 - 214
[22] Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial
Pan, Jing
Tan, Yue
Wang, Guoling
Deng, Biping
Ling, Zhuojun
Song, Weiliang
Seery, Samuel
Zhang, Yanlei
Peng, Shuixiu
Xu, Jinlong
Duan, Jiajia
Wang, Zelin
Yu, Xinjian
Zheng, Qinlong
Xu, Xiuwen
Yuan, Ying
Yan, Fangrong
Tian, Zhenglong
Tang, Kaiting
Zhang, Jiecheng
Chang, Alex H.
Feng, Xiaoming
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (30) : 3340 - +
[23] Efficacy and safety of chimeric antigen receptor T cells targeting BCMA and GPRC5D in relapsed or refractory multiple myeloma
Yang, Xu
Wang, Feiqing
Yuan, Xiaoshuang
Yang, Bo
Chen, Juan
Cheng, Jinyang
Liu, Guangyang
Tang, Dongxin
Xu, Xiao
Wang, Sanbin
He, Zhixu
Liu, Yang
Li, Yanju
FRONTIERS IN IMMUNOLOGY, 2024, 15
[24] The THINK clinical trial: Preliminary evidence of clinical activity of NKG2D chimeric antigen receptor T cell therapy (CYAD-01) in acute myeloid leukemia
Sallman, David A.
Brayer, Jason B.
Poire, Xavier
Kerre, Tessa
Lewalle, Philippe
Wang, Eunice S.
Verma, Bikash
Breman, Eytan
Davila, Marco
Braun, Nathalie
Lonez, Caroline
Gilham, David E.
Lehmann, Frederic F.
CANCER RESEARCH, 2018, 78 (13)
[25] Remissions of Multiple Myeloma during a First-in-Humans Clinical Trial of T Cells Expressing an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor
Ali, Syed Abbas
Shi, Victoria
Wang, Michael
Stroncek, David
Maric, Irina
Brudno, Jennifer N.
Stetler-Stevenson, Maryalice
Rose, Jeremy J.
Feldman, Steven
Hansen, Brenna
Hakim, Frances T.
Gress, Ronald E.
Kochenderfer, James N.
BLOOD, 2015, 126 (23)
[26] γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-inhuman trial
Cowan, Andrew J.
Pont, Margot J.
Sather, Blythe
Turtle, Cameron J.
Till, Brian G.
Libby, Edward N.
Coffey, David G.
Tuazon, Sherilyn A.
Wood, Brent
Gooley, Ted
Wu, Vicky Q.
Voutsinas, Jenna
Song, Xiaoling
Shadman, Mazyar
Gauthier, Jordan
Chapuis, Aude G.
Milano, Filippo
Maloney, David G.
Riddell, Stanley R.
Green, Damian J.
LANCET ONCOLOGY, 2023, 24 (07): : 811 - 822
[27] PHASE I, OPEN-LABEL TRIAL OF ANTI-BCMA CHIMERIC ANTIGEN RECEPTOR T CELLS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
Zhang, W.
Zhao, W.
Liu, J.
He, A.
Chen, Y.
Cao, X.
Yang, N.
Wang, B.
Zhang, P.
Zhang, Y.
Wang, F.
Lei, B.
Gu, L.
Yang, Y.
Bai, J.
Zhang, R.
Wang, X.
Ma, X.
Wang, J.
Wang, J.
Wei, L.
Zhang, J.
Zang, X.
Zhuang, Q.
Fan, F. X.
HAEMATOLOGICA, 2017, 102 : 2 - 3
[28] A phase I global trial targeting multiple solid and hematologic malignancies through a NKG2D receptor-based CAR-T immunotherapy
Verma, B.
Awada, A.
Aftimos, P.
Lewalle, P.
Meuleman, N.
Machiels, J-P.
Catala, G.
Vandenneste, E.
Brayer, J.
Sallman, D.
Sahebjam, S.
Kerre, T.
Rottey, S.
Odunsi, K.
Wang, E. S.
Santanam, U.
Lonez, C.
Gilham, D. E.
Lehmann, F.
ANNALS OF ONCOLOGY, 2017, 28
[29] B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) for Multiple Myeloma (MM): Initial Safety and Efficacy from a Phase I Study
Cohen, Adam D.
Garfall, Alfred L.
Stadtmauer, Edward A.
Lacey, Simon Francis
Lancaster, Eric
Vogl, Dan T.
Dengel, Karen
Ambrose, David E.
Chen, Fang
Plesa, Gabriela
Kulikovskaya, Irina
Gonzalez, Vanessa E.
Gupta, Minnal
Young, Regina M.
Carey, Tenesia
Ferthio, Regina
Weiss, Brendan M.
Richardson, Celeste
Isaacs, Randi E.
Melenhorst, J. Joseph
Levine, Bruce L.
June, Carl H.
Milone, Michael C.
BLOOD, 2016, 128 (22)
[30] Preliminary results of a first in human Phase 1 clinical trial to demonstrate safety and feasibility of chimeric antigen receptor T (CART) cells directed against c-Met in the treatment of breast cancer
Tchou, J.
Zhang, P. J.
Levine, B. L.
Zhao, Y.
Matro, J.
DeMichele, A.
Amy, C.
Schuchter, L.
Plesa, G.
Vonderheide, R. H.
June, C.
CANCER RESEARCH, 2017, 77

← 1 2 3 4 5 →